Danaher (NYSE:DHR) Rating Reiterated by Royal Bank of Canada

Danaher (NYSE:DHR)‘s stock had its “outperform” rating reaffirmed by investment analysts at Royal Bank of Canada in a research report issued on Friday, Benzinga reports. They presently have a $300.00 price target on the conglomerate’s stock. Royal Bank of Canada’s price target suggests a potential upside of 11.45% from the stock’s current price.

A number of other equities analysts have also recently weighed in on the stock. Evercore ISI lowered their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Robert W. Baird increased their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Bank of America increased their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Jefferies Financial Group began coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Finally, Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Trading Up 1.7 %

Shares of Danaher stock traded up $4.46 during mid-day trading on Friday, hitting $269.17. The stock had a trading volume of 118,798 shares, compared to its average volume of 2,772,358. The firm has a 50-day moving average of $260.98 and a two-hundred day moving average of $255.61. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $199.37 billion, a P/E ratio of 45.52, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. Sell-side analysts forecast that Danaher will post 7.59 earnings per share for the current year.

Insider Activity

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Danaher

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cape Investment Advisory Inc. purchased a new stake in Danaher in the fourth quarter valued at $25,000. Tsfg LLC lifted its position in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the second quarter valued at $25,000. nVerses Capital LLC acquired a new position in Danaher in the second quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher in the first quarter valued at $30,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.